Oxurion NV logo

OXUR - Oxurion NV Share Price

€2.59 -0.0  -0.2%

Last Trade - 3:30pm

Small Cap
Market Cap £85.6m
Enterprise Value £54.5m
Revenue £2.93m
Position in Universe 532nd / 847
Unlock OXUR Revenue
Relative Strength (%)
1m -3.23%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -21.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
13.8 11.2 7.10 9.06 5.32 3.95 1.67 1.33 -22.1%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Oxurion NVrevenues decreased 30% to EUR1.3M. Net loss decreased 61%to EUR13.1M. Revenues reflect a decrease in demand for theCompany's products and services due to unfavorable marketconditions. Lower net loss reflects Impairment lossesdecrease from EUR16.9M (expense) to EUR0K, Research anddevelopment expenses decrease of 25% to EUR9M (expense),Selling expenses decrease of 48% to EUR1.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


OXUR Revenue Unlock OXUR Revenue

Net Income

OXUR Net Income Unlock OXUR Revenue

Normalised EPS

OXUR Normalised EPS Unlock OXUR Revenue

PE Ratio Range

OXUR PE Ratio Range Unlock OXUR Revenue

Dividend Yield Range

OXUR Dividend Yield Range Unlock OXUR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
OXUR EPS Forecasts Unlock OXUR Revenue
Profile Summary

Oxurion NV, formerly known as ThromboGenics NV, is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The Company is active domestically, as well as operates through offices located in the United States and Ireland.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated May 30, 2006
Public Since July 7, 2006
No. of Shareholders: n/a
No. of Employees: 77
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Euronext - Brussels
Shares in Issue 38,291,950
Free Float (0.0%)
Eligible for
OXUR Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for OXUR
Upcoming Events for OXUR
Frequently Asked Questions for Oxurion NV
What is the Oxurion NV share price?

As of 3:30pm, shares in Oxurion NV are trading at €2.59, giving the company a market capitalisation of £85.6m. This share price information is delayed by 15 minutes.

How has the Oxurion NV share price performed this year?

Shares in Oxurion NV are currently trading at €2.59 and the price has moved by -13.79% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Oxurion NV price has moved by -22.16% over the past year.

What are the analyst and broker recommendations for Oxurion NV?

Of the analysts with advisory recommendations for Oxurion NV, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Oxurion NV is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Oxurion NV next release its financial results?

Oxurion NV is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Oxurion NV dividend yield?

Oxurion NV does not currently pay a dividend.

Does Oxurion NV pay a dividend?

Oxurion NV does not currently pay a dividend.

When does Oxurion NV next pay dividends?

Oxurion NV does not currently pay a dividend.

How do I buy Oxurion NV shares?

To buy shares in Oxurion NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Oxurion NV?

Shares in Oxurion NV are currently trading at €2.59, giving the company a market capitalisation of £85.6m.

Where are Oxurion NV shares listed? Where are Oxurion NV shares listed?

Here are the trading details for Oxurion NV:

Country of listing: Belgium
Exchange: BRU
Ticker Symbol: OXUR
What kind of share is Oxurion NV?

Based on an overall assessment of its quality, value and momentum, Oxurion NV is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Oxurion NV share price forecast 2021?

Shares in Oxurion NV are currently priced at €2.59. At that level they are trading at 0.13% discount to the analyst consensus target price of 0.00.

Analysts covering Oxurion NV currently have a consensus Earnings Per Share (EPS) forecast of -0.8 for the next financial year.

How can I tell whether the Oxurion NV share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oxurion NV. Over the past six months, the relative strength of its shares against the market has been -11.98%. At the current price of €2.59, shares in Oxurion NV are trading at -4.2% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Oxurion NV PE Ratio?

We were not able to find PE ratio data for Oxurion NV.

Who are the key directors of Oxurion NV?

Oxurion NV's management team is headed by:

Patrik De Haes - CEO
Andy De Deene - VRD
Thomas Clay - NEC
David Guyer - NED
Emmanuele Attout - NID
Philippe Vlerick - NID
Vinciane Vangeersdaele - DSL
Adrienne Graves - NID
Julie Binon - CHO
Grace Chang - OTH
Tom Graney - CFO
Alan Stitt - CSO
Who are the major shareholders of Oxurion NV?

Here are the top five shareholders of Oxurion NV based on the size of their shareholding:

Clay (Thomas Moragne) Individual Investor
Percentage owned: 8.78% (3.36m shares)
Vlerick (Philippe) Individual Investor
Percentage owned: 6.07% (2.32m shares)
Novartis AG Corporation
Percentage owned: 5.69% (2.18m shares)
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund
Percentage owned: 0.79% (303k shares)
BNP Paribas Asset Management Belgium S.A. Investment Advisor
Percentage owned: 0.53% (205k shares)
Similar to OXUR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.